Navigation Links
Lead Plaintiff's Attorney In Forest Pharmaceuticals Case Says $313 Million Award Is 'Tip of the Iceberg' of Future Off-Label Marketing Lawsuits

SHORT HILLS, N.J., Sept. 17 /PRNewswire/ -- Fresh off his victory for a whistle-blower in the Forest Pharmaceuticals, Inc. lawsuit, attorney David Stone is setting his sights on the billions of dollars of settlements he expects awarded in future legal actions involving off-labeling marketing practices.

"The award of $313 million in the Forest Pharmaceuticals case is just the tip of the iceberg in comparison to the amount of off-label marketing kick-back settlements we'll see in the future," Stone said. "Pharmaceutical companies are under increasing competitive pressures. Unfortunately, in their attempts to increase product sales, many are engaging in deceptive and illegal conduct, which has endangered patients' health and even their lives, as well as cost taxpayers billions of healthcare dollars."

Stone, managing partner of Short Hills, NJ-based law firm Stone & Magnanini LLP, represented a physician who originally brought Forest Pharmaceuticals' illegal marketing practices to the government's attention in a 2001 False Claims Act lawsuit. Stone previously served as head of the False Claims Act department for renowned litigator, David Boies, and headed that firm's New Jersey office.

Stone explained that the Federal government is focusing more broadly on pharmaceutical industry marketing practices. The Department of Justice and the Office of the Inspector General are scrutinizing practices tied to relations between drug makers and the physicians who endorse their products; the content and distribution of product promotional materials; and the complex inter-relationship of manufacturers, physicians, insurers and others in the drug-delivery chain.

Forest Pharmaceuticals recently agreed to settle civil and criminal claims based on off-label marketing and kick-backs to physicians for the antidepressant drugs Celexa and Lexapro, and Levothoid, a drug used to treat hypothyroidism, for more than $313 million.  

Stone & Magnanini LLP specializes in False Claims Act cases in the pharmaceutical fraud area – initiating legal actions on behalf of individuals, as well as for third-party payers such as insurance companies and HMOs. The firm also works with pharmaceutical companies to review their existing practices and procedures in light of current DOJ and OIG policy-related initiatives. Visit

Contact:  Mark Clemente, Steinreich Communications, 201-498-1600,

SOURCE Stone & Magnanini LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Plaintiffs and Novartis Pharmaceuticals Corporation, a US Subsidiary of Novartis AG, Agree to Resolve All Gender Discrimination Claims Associated With Class Action
2. Fort Worth Attorney Dwain Dent Comments on Final Judgment in Case That Left Hundreds of Babies Dead or Injured
3. Remarks as Prepared for Delivery By Attorney General Eric Holder at the AstraZeneca Settlement Announcement
4. Relators Attorneys Comment On AtriCure/DOJ Proposed Settlement
5. Whistleblowers Attorney Says Pfizers Guilty Plea Today Opens New Chapter on Aggressive Enforcement of Pharma Companies
6. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Forest Pharmaceuticals Agrees to Guilty Plea for Violating FDA Laws
9. NHLBI Grant Awarded to Wake Forest, Pitt to Improve Banked Blood
10. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
11. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
Post Your Comments:
(Date:11/24/2015)... November 24, 2015 Sectra (STO: ... has entered into a multi-year agreement to deploy ... investment will provide the Breast Center a future-proof platform ... (STO: SECT B) announces that Breast Center of ... deploy Breast Imaging PACS in its two freestanding imaging ...
(Date:11/24/2015)...   HeartWare International, Inc . (NASDAQ: HTWR ... technologies that are revolutionizing the treatment of advanced heart ... Doug Godshall is scheduled to present at ... on December 1, 2015 at 3:00 p.m. ET.  The ... New York . . ...
(Date:11/24/2015)... , November 24, 2015 ... of the University of Bern ... Nutrition of the Bern University Hospital "Inselspital" are proud ... develop a novel generation artificial pancreas. Combining a fully ... for diabetic patients with the unequalled accuracy of an ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... , ... Many people know of the common symptoms of low thyroid hormone ... But many people who find their cholesterol levels and weight are creeping up are ... if they don’t have any of the other symptoms. , Thyroid hormone plays a ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Students and parents ... awarded to winners of the Create Real Impact awards. California Casualty is ... help stem the tide of distracted and reckless driving, the number one killer of ...
(Date:11/24/2015)... ... November 24, 2015 , ... Eric C. Seidel, DMD ... benefits of the revolutionary BIOLASE WaterLase iPlus 2.0™ system. This advanced laser technology ... by a dentist in Gettysburg, PA . From routine visits to cosmetic ...
(Date:11/24/2015)... AZ (PRWEB) , ... November 24, 2015 , ... Young ... 2.0™ treatments from Dr. Angela Wolfman and Dr. Kedar S. Lele, who are ... for frenectomies, cavities and fillings, the WaterLase iPlus 2.0™ system causes minimal discomfort and ...
(Date:11/24/2015)... ... November 24, 2015 , ... In an article ... and variables that determine which patients are or are not eligible for bariatric surgery. ... a BMI over 40, are more than 100 pounds overweight, or have a BMI ...
Breaking Medicine News(10 mins):